The Hidden Heart Disease: Shedding Light on Cardiac Amyloidosis.
作者信息
Tsai Cheng-Hsuan, Lin Yen-Hung, Wu Yen-Wen
机构信息
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University.
Cardiovascular Center, National Taiwan University Hospital, Taipei.
出版信息
Acta Cardiol Sin. 2023 Jul;39(4):544-545. doi: 10.6515/ACS.202307_39(4).20230526A.
Abstract
摘要
相似文献
1
The Hidden Heart Disease: Shedding Light on Cardiac Amyloidosis.
Acta Cardiol Sin. 2023 Jul;39(4):544-545. doi: 10.6515/ACS.202307_39(4).20230526A.
2
Cardiac Transthyretin Amyloidosis: Hidden in Plain Sight.
Case Rep Med. 2021 Dec 7;2021:2551964. doi: 10.1155/2021/2551964. eCollection 2021.
3
Prognostic value of depressed midwall systolic function in cardiac light-chain amyloidosis.
J Hypertens. 2014 May;32(5):1121-31; discussion 1131. doi: 10.1097/HJH.0000000000000120.
4
Accelerated junctional rhythm (AJR) revealing light-chain cardiac amyloidosis: A case report with literature review.
Ann Med Surg (Lond). 2022 Mar 3;75:103410. doi: 10.1016/j.amsu.2022.103410. eCollection 2022 Mar.
5
Light-Chain (AL) Cardiac Amyloidosis Presenting as Heart Failure With Reduced Ejection Fraction.
Cureus. 2024 Feb 29;16(2):e55271. doi: 10.7759/cureus.55271. eCollection 2024 Feb.
6
Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation.
JACC Heart Fail. 2020 Jun;8(6):461-468. doi: 10.1016/j.jchf.2019.12.013. Epub 2020 May 6.
7
Cardiac amyloidosis: updates in diagnosis and management.
Arch Cardiovasc Dis. 2013 Oct;106(10):528-40. doi: 10.1016/j.acvd.2013.06.051. Epub 2013 Sep 23.
8
Harnessing Cardiac Regeneration as a Potential Therapeutic Strategy for AL Cardiac Amyloidosis.
Curr Cardiol Rep. 2020 Jan 13;22(1):1. doi: 10.1007/s11886-020-1252-3.
9
Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure.
Transplantation. 2010 Oct 27;90(8):905-11. doi: 10.1097/TP.0b013e3181f10edb.
10
Light-chain cardiac amyloidosis.
Curr Probl Cancer. 2017 Mar-Apr;41(2):144-156. doi: 10.1016/j.currproblcancer.2016.11.004. Epub 2016 Nov 17.
引用本文的文献
1
Effect of Tafamidis on Clinical and Functional Parameters in Transthyretin Amyloid Cardiomyopathy.
JACC Adv. 2025 Feb;4(2):101511. doi: 10.1016/j.jacadv.2024.101511. Epub 2024 Dec 19.
2
2025 Update Consensus of Tc-Pyrophosphate Scintigraphy in the Transthyretin Cardiac Amyloidosis from the Taiwan Society of Cardiology and the Society of Nuclear Medicine of the Republic of China.
Acta Cardiol Sin. 2025 Jan;41(1):55-71. doi: 10.6515/ACS.202501_41(1).20241027A.
本文引用的文献
1
Efficacy of Tafamidis in Patients with Ala97Ser Hereditary Transthyretin Cardiac Amyloidosis: A Six-Month Follow-Up Study.
Acta Cardiol Sin. 2023 Jul;39(4):619-627. doi: 10.6515/ACS.202307_39(4).20221116A.
2
2023 Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis.
Acta Cardiol Sin. 2023 Jul;39(4):511-543. doi: 10.6515/ACS.202307_39(4).20230610A.
3
Tafamidis Treatment Decreases Tc-Pyrophosphate Uptake in Patients With Hereditary Ala97Ser Transthyretin Amyloid Cardiomyopathy.
JACC Cardiovasc Imaging. 2023 Jun;16(6):866-867. doi: 10.1016/j.jcmg.2022.12.016. Epub 2023 Feb 8.
4
Reverse cardiac remodelling and dysfunction in A97S transthyretin cardiac amyloidosis after tafamidis treatment.
ESC Heart Fail. 2022 Dec;9(6):4335-4339. doi: 10.1002/ehf2.14165. Epub 2022 Sep 20.
5
2021 Advocacy Statements for the Role of Tc-Pyrophosphate Scintigraphy in the Diagnosis of Transthyretin Cardiac Amyloidosis: A Report of the Taiwan Society of Cardiology and the Society of Nuclear Medicine of the Republic of China.
Acta Cardiol Sin. 2021 May;37(3):221-231. doi: 10.6515/ACS.202105_37(3).20210420A.
6
Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association.
Circulation. 2020 Jul 7;142(1):e7-e22. doi: 10.1161/CIR.0000000000000792. Epub 2020 Jun 1.
7
Cardiac manifestations and prognostic implications of hereditary transthyretin amyloidosis associated with transthyretin Ala97Ser.
J Formos Med Assoc. 2020 Mar;119(3):693-700. doi: 10.1016/j.jfma.2019.08.027. Epub 2019 Sep 11.
8
Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.
J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891. doi: 10.1016/j.jacc.2019.04.003.
9
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.
10
Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness.
Eur Heart J. 2016 Jun 14;37(23):1826-34. doi: 10.1093/eurheartj/ehv583. Epub 2015 Nov 3.
Zotero 插件